Eli Lilly (LLY -0.52%) is a leader in this space, but several companies are looking to take its crown. Could Viking Therapeutics successfully challenge Eli Lilly? Viking Therapeutics has key catalysts aheadViking Therapeutics is a clinical-stage biotech. Viking Therapeutics doesn't have a single approved product, generates no revenue, is not profitable, and may not be for a while. But that significant upside potential also comes with a hefty dose of risk: Viking Therapeutics' shares will fall off a cliff if VK2735 disappoints.